New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
07:03 EDTDRTXDurata Therapeutics price target raised to $22 from $18 at Credit Suisse
Credit Suisse believes Outperform rated Durata's announcement to see approval of a single dose regimen for Dalvance will increase compliance and penetration, resulting in greater sales potential. The firm continues to view Durata shares as undervalued and raised its price target to $22 from $18.
News For DRTX From The Last 14 Days
Check below for free stories on DRTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 18, 2014
08:06 EDTDRTXDurata Therapeutics announces U.S. launch of Dalvance
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use